

Zolgensma Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

The Business Research Company's Zolgensma Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, February 10, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



How is the Historical and Forecasted Growth Shaping Up the <u>Zolgensma Market</u>? In its recent historical growth, the Zolgensma market has recorded an XX% compound annual growth rate CAGR. This growth results from rising awareness of genetic disorders, increased healthcare expenditure, and the rising prevalence of genetic testing. The market is set to surge from \$XX million in 2024 to \$XX million in 2025.

Looking ahead, the Zolgensma market is anticipated to register XX% future CAGR FCAGR. By 2029, it's expected to burgeon to \$XX million. Key factors driving this growth are the rising interest in personalized medicine approaches, increased global healthcare spending, growth in telemedicine, a heightened focus on treating rare diseases, and advancements in digital health technologies.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp

What is Driving the Growth of the Zolgensma Market?

The increasing incidence of Spinal Muscular Atrophy SMA prompts the growth of the Zolgensma market. Characterised by the degeneration of motor neurons in the spinal cord, SMA leads to progressive muscle weakness and atrophy, primarily affecting infants and young children. The escalating incidence of SMA can be chalked up to improved genetic testing and newborn screening programs that aid in early and accurate diagnoses.

Zolgensma addresses the core genetic cause of the disease by delivering a functional copy of the SMN1 gene to SMA patients. In turn, it revives the production of the survival motor neuron SMN protein, vital for motor function and muscle strength, improving motor skills and survival in affected infants and children. For instance, as of November 2022, 118 out of 161 patients with SMA Type 1 were over two years old and living without the need for permanent ventilatory support. This metric testifies to the increasing incidence of SMA, thereby driving the Zolgensma market growth.

Order Your Report Now For A Swift Delivery: <u>https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report</u>

Which Major Industry Players Are Dominating the Zolgensma Market? Market dominants such as Novartis AG are heavily influencing the dynamics of the Zolgensma market. These prominent players focus on advancements in gene therapy technologies and strategize to expand their footprints in the market.

What Are the Emerging Trends in the Zolgensma Market?

One key trend in the Zolgensma market is the focus on strategic investments to bolster production capacity, expand geographic reach, and expedite research and development efforts for innovative gene therapy solutions. In April 2022, a case in point is Novartis AG. The Switzerland-based pharmaceutical corporation received commercial licensure approval from the United States Food and Drug Administration for its multi-product gene therapy manufacturing facility in Durham, North Carolina.

How Is the Zolgensma Market Segmentated?

The Zolgensma market report segments the market as follows – 1 By Indication: Spinal Muscular Atrophy SMA Type 1; SMA Type 2; SMA Type 3; Pre-symptomatic Spinal Muscular Atrophy SMA

2 By Age Group: Pediatric Infants And Children; Adults

3 By Distribution Channel: Hospitals; Specialty Clinics; Pharmacies

What are the Regional Insights into the Zolgensma Market?

Among the global regions, North America was the largest market player for Zolgensma in 2024. However, the Zolgensma market report also covers other regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Cell and Gene Therapy Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-marketreport Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell & Gene Therapy Manufacturing Services Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report</u>

About The Business Research Company

Learn More About The Business Research Company. With a repertoire over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has carved a niche for itself with comprehensive, data-rich research and insights backed by 1,500,000 datasets, the power of in-depth secondary research, and unique inputs from industry leaders. This gives you the information you need to stay ahead of the competition.

Contact us at: The Business Research Company: <u>https://www.thebusinessresearchcompany.com/</u> Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on: LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> YouTube: <u>https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ</u> Global Market Model: <u>https://www.thebusinessresearchcompany.com/global-market-model</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/784666071

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.